Abstract 188P
Background
A thorough investigation of the tumor cells and immune microenvironment within the lead-edge area is essential for understanding the mechanisms behind the progression of ICC and devising a targeted therapy in the hope of providing clinical benefits for patients.
Methods
Here, we conducted an analysis based on single-cell RNA sequencing (scRNA-seq) and spatial transcriptome (ST) on samples from the tumor core, paired non-tumorous tissue, and the leading-edge area obtained from 9 ICC patients to delineate the properties of cancer cells, immune microenvironment, and the intricate intercellular interactions within. The analysis results were further validated using H&E staining, multiple immunofluorescence staining (IHC), and a large transcriptome dataset.
Results
Tumor cells at the leading-edge area exhibit a heightened capacity for proliferation compared to those in the tumor core, often found in close proximity to the stroma, including endothelial cells and POSTN+ FAP+ fibroblasts. Within this region, CD8+ T cells are characterized by a naive phenotype, displaying low levels of cytotoxicity and exhaustion, a condition that may be linked to the impaired antigen-presenting capabilities of antigen-presenting cells (APCs). MAIT cells, which are the predominant CD8+ T cell subset infiltrating the leading-edge area of ICC, have been observed to recruit SPP1+ macrophages and are co-localized with POSTN+ cancer-associated fibroblasts (CAFs) in the stromal compartment. The presence of SPP1+ macrophages could potentially foster tumor progression through the activation of CD44 in tumor cells, as well as by their proangiogenic effects.
Conclusions
Utilizing scRNA-seq and spatial transcriptome technologies, our research delineates the distinct characteristics of ICC tumor cells within the leading-edge area, revealing how they interact with and influence the surrounding stroma to sculpt the immune microenvironment. These orchestrated interactions within the tumor milieu offer valuable insights and pinpoint potential therapeutic targets for intervention.
Legal entity responsible for the study
Peking University.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
31P - Peripheral-blood Immune-predictors of pathological complete response in patients with triple-negative breast cancer undergoing neoadjuvant chemo-immunotherapy
Presenter: Celeste Santoro
Session: Poster Display session
32P - Immune T cell subsets dynamics in the early TNBC treatment setting
Presenter: Rocío Martín Lozano
Session: Poster Display session
33P - Tumor-specific CD4 Th1 responses in long-term responder melanoma patients treated with immune checkpoint inhibitors.
Presenter: Jessica Mathiot
Session: Poster Display session
34P - Linking early immunity changes to clinical outcomes in cutaneous squamous cell carcinoma following anti-programmed death cell-1 (PD-1) treatment
Presenter: Marcella Scala
Session: Poster Display session
37P - Lymphocyte Subpopulation Balances as a Blood Biomarker for Immune-Related Adverse Events in Patients Receiving Immune Checkpoint Inhibitors
Presenter: Mireille Langouo fontsa
Session: Poster Display session
38P - Biomarkers predictive of response to immune checkpoint inhibitor therapy in patients with metastatic melanoma
Presenter: Eliza Bob
Session: Poster Display session
39P - Analysis of the immune response patterns in localized prostate cancer
Presenter: Sara Merler
Session: Poster Display session
40P - MANIFEST: A Multiomic Profiling Platform for Immuno-Oncology Biomarker Discovery
Presenter: Zayd Tippu
Session: Poster Display session
41P - Total tumor burden and radiomics to evaluate response in dose escalation studies: Roginolisib (IOA-244), a highly selective PI3Kd inhibitor in metastatic uveal melanoma patients
Presenter: Anna Di Giacomo
Session: Poster Display session